

**3<sup>rd</sup> Workshop of the European Network on Viral Vaccine Processes (ENVVP)  
25-26 November 2013, in Frankfurt am Main, Germany**

**Programme**

---

**Monday, November 25, 2013**

---

**VACCINE DESIGN**

---

- 09:00 **INVITED LECTURE**  
**Emerging viruses: a veterinary view at challenges of control at the interfaces of wildlife-livestock-humans**  
T. Harder, Friedrich-Loeffler-Institut, Greifswald-Insel Riems/D
- 
- 09:30 **INVITED LECTURE**  
**Development and production of nonspreading Rift Valley fever vaccines**  
R. Moormann, Wageningen University, Lelystad and Utrecht University/NL; N. Ohreshkova, J. Kortekaas, Wageningen, Lelystad/NL
- 
- 10:00 **INVITED LECTURE**  
**Title tbd (tentative title: Genetic vaccines based on MVA)**  
G. Sutter, University of Munich/D
- 
- 10:30 **New approaches for designing, control and manufacturing viral vaccines**  
C. Pereira, Instituto Butantan, São Paulo/BR
- 
- 10:50 **A platform to determine the impact of influenza virus hemagglutinin N-glycosylation on immunogenicity**  
J. Hütter, MPI of Colloids and Interfaces, Potsdam/D; J.V. Rödig, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; D. Höper, Friedrich-Loeffler-Institut, Greifswald - Insel Riems/D; P.H. Seeberger, MPI of Colloids and Interfaces, Potsdam/D; U. Reichl, MPI for Dynamics of Complex Technical Systems and University of Magdeburg/D; E. Rapp, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; B. Lepenies, MPI of Colloids and Interfaces, Potsdam/D
- 

11:10 Coffee Break

---

**CELL SUBSTRATES AND ENGINEERING**

---

- 11:30 **Single step cloning-titration method: enabling tools for virus producer cell line development and engineering**  
A.F. Rodrigues, A.S. Oliveira, M.R. Guerreiro, H. Tomas, M.J.T. Carrondo, P.M. Alves, A.S. Coroadinha, IBET - Instituto de Biologia Experimental e Tecnológica, Oeiras/P
- 
- 11:50 **Adaptation of a vaccine virus to production in suspension cultures**  
I. Jordan, V. Sandig, ProBioGen AG, Berlin/D
- 
- 12:10 **Human CAP cells as novel platform for production of vaccines**  
G. Schiedner, CEVEC Pharmaceuticals GmbH, Cologne/D
- 
- 12:30 **Capturing cell's quality: how to measure the infectability of PER.C6<sup>®</sup> cells by viruses?**  
S.M. Mercier, B. Diepenbroek, Crucell, Leiden/NL; R.H. Wijffels, M. Streefland, Wageningen University/NL
- 

13:00 Lunch Break

---

**BIOREACTION / UPSTREAM**

---

- 14:00 **INVITED LECTURE**  
**Towards large scale AAV vector production: process development, bottlenecks, and perspectives**  
O.-W. Merten, Généthon, Evry Cedex/F
- 
- 14:30 **INVITED LECTURE**  
**Manufacturing of AAV gene-therapy products**  
A. van Oorschot, uniQure, Amsterdam/NL
-

**3<sup>rd</sup> Workshop of the European Network on Viral Vaccine Processes (ENVVP)  
25-26 November 2013, in Frankfurt am Main, Germany**

**Programme**

- 
- 15:00 **Viral vector production in the integrity™ iCELLis® disposable fixed-bed bioreactor from bench-scale to industrial scale**  
A. Lennaert, S. Knowles, J.C. Drugmand, J. Castillo, ATMI LifeSciences, Brussels/B
- 
- 15:20 **Continuous cell culture-based influenza vaccine production**  
T. Frensing, S. Heldt, I. Behrendt, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; I. Jordan, ProBioGen AG, Berlin/D; Y. Genzel, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; U. Reichl, MPI for Dynamics of Complex Technical Systems and University of Magdeburg/D
- 
- 15:40 **Scale-down of the inactivated polio vaccine production process**  
Y.E. Thomassen, A.G. van't Oever, M. Vinke, A. Spiekstra, L.A. van der Pol, W.A.M. Bakker, Institute for Translational Vaccinology, Bilthoven/NL
- 
- 16:00 Coffee Break
- 
- ONCOLYTIC VIRUSES**
- 
- 16:15 **INVITED LECTURE**  
**Viral gene transfer vectors: regulatory aspects and innovations in surface targeting**  
C.J. Buchholz, Paul-Ehrlich-Institut, Langen/D
- 
- 16:45 **INVITED LECTURE**  
**Oncolytic virus production and purification challenges for human clinical trials: case study measles virus**  
M. Federspiel, Mayo Clinic, Rochester, MN/USA
- 
- 17:15  
– **POSTER SESSION**  
18:15
- 
- P.01 **From bench scale to industrial scale: using the integrity™ iCELLis® disposable fixed-bed bioreactor to scale-up production of viral entities**  
J.C. Drugmand, S. Knowles, N. Vertommen, J. Castillo, F. Debras, ATMI LifeSciences, Brussels/B
- 
- P.02 **Improving adenovirus purification by using enhanced membrane chromatography**  
P. Nestola, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; L. Villain, Sartorius Stedim Biotech, Gottingen/D; C. Peixoto, P.M. Alves, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; J.P.B. Mota, Requimte/CQFB, FCT/UNL, Caparica/P; M.J.T. Carrondo, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P
- 
- P.03 **Improving viral vaccine production by interfering in the viral life cycle and by identifying new producer cell lines**  
D. Oosterhoff, L. van der Pol, W.A. Bakker, Intravacc, Bilthoven/NL
- 
- 19:00 **Dinner**
-

**3<sup>rd</sup> Workshop of the European Network on Viral Vaccine Processes (ENVVP)  
25-26 November 2013, in Frankfurt am Main, Germany**

**Programme**

---

**Tuesday, November 26, 2013**

---

**PURIFICATION / DOWNSTREAM / PROCESS CONTROL**

---

09:00 **Emerging new tools for improving downstream processing for viral vaccine and viral vectors**

P. Nestola, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; L. Villain, Sartorius Stedim Biotech, Göttingen/D; C. Peixoto, P.M. Alves, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P; J.P.B Mota, Requite/CQFB, Departamento de Química, FCT/UNL, Caparica/P; M.J.T Carrondo, IBET- Instituto de Biologia Experimental e Tecnológica, Oeiras/P

---

09:20 **Can membrane chromatography streamline influenza virus purification?**

A. Cvetkovic, R. Gantier, Pall Corporation, Westborough, MA/USA; A. Onraedt, Pall International, Fribourg/CH

---

09:40 **Purification of Enterovirus 71 like particles for vaccine production by the use of different membrane adsorbers**

M. Meininger, MPI for Dynamics of Complex Technical Systems, Magdeburg/D; R. Djurup, Rebidu, Gentofte/DK; L. Villain, Sartorius-Stedim Biotech GmbH, Göttingen/D; J. Cardoso, Sentinext Therapeutics Sdn Bhd, Penang/MAL; U. Reichl, M. Wolff, MPI for Dynamics of Complex Technical Systems, Magdeburg/D

---

10:00 **Ultrafiltration membranes in downstream processing for vaccine production**

T. Schleuss, H.-H. Hörl, U. Grummert, Sartorius Stedim Biotech GmbH, Göttingen/D; C. Peixoto, D. Martins, IBET, Oeiras/P

---

10:20 **High-throughput process development for the purification of virus-like particles**

C. Ladd Effio, L. Wenger, S.A. Oelmeier, J. Hubbuch, Karlsruhe Institute of Technology (KIT)/D

---

10:40 Coffee Break

---

11:00 **Introduction of PAT to improve the efficiency and robustness of vaccine development and manufacturing**

A. Strancar, BIA Separations, Ajdovscina/SLO

---

11:20 **Best practices in nucleic acid removal from vaccine processes**

F. Appel, Merck Millipore, Darmstadt/D

---

11:40 **Scale-up study: single use bioprocessing for influenza virus**

J. Royce, GE Healthcare Life Sciences, Uppsala/S

---

12:00 **Purification of cell culture-derived influenza virus via continuous size exclusion chromatography**

T. Kröber, L.M. Fischer, M.W. Wolff, U. Reichl, MPI for Dynamics of Complex Technical Systems, Magdeburg/D

---

12:20 **Wrap-up discussion**

-

13:00

---